Zusammenfassung
Die klinische Wirksamkeit und Verträglichkeit eines neuen, intravenös verträglichen Pseudomonas-Hyperimmunglobulins wurden im Rahmen einer prospektiven randomisierten Studie an 30 Patienten untersucht. Wenn auch die statistische Auswertung der meßbaren Parameter keine relevanten Unterschiede zwischen Therapie- (n=15) und Kontrollgruppe (n=15) erbrachte, so war doch der klinische Verlauf in der Therapiegruppe deutlich besser: An den Folgen einer Infektion mitPseudomonas aeruginosa starben in der Kontrollgruppe drei Patienten, in der Therapiegruppe keiner. Die Verträglichkeit des Präparates war sehr gut.
Summary
The clinical efficacy and safety of a new pseudomonas hyperimmune globulin for intravenous administration were examined in 30 patients in a prospective randomized study. Although the statistical evaluation of the measurable parameters did not show relevant differences between the therapy group (n=15) and the controls (n=15), the clinical course of the disease was markedly better in patients treated with hyperimmune globulin. In the control group, three patients died fromPseudomonas aeruginosa infections, but none in the therapy group. The preparation was very well tolerated.
Article PDF
Avoid common mistakes on your manuscript.
Literatur
Gould, I. M., Wise, R.: Pseudomonas aeruginosa: clinical manifestations and management. Lancet (1985) 1224–1226.
Bishop, J. F., Schimpff, S. C., Diggs, C. H., Wiernik, P. H. Infections during intensive chemotherapy for Non-Hodgkin's lymphoma. Ann. Int. Med. 95 (1981) 549–555.
Marget, W., Mar, P. J., Jaspers, L., Possinger, K., Haselberger, H. Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients. Infection 13 (1985) 120–124
Holder, I. A., Naglich, J. G. Experimental studies on pathogenesis of infections due toPseudomonas aeruginosa, treatment with intravenous immune globulin. Am. J. Med. 76 (1984) 161–167.
Pollack, M., Young, L. S. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset ofPseudomonas aeruginosa septicemia in man. J. Clin. Inv. 63 (1979) 276–286.
Cross, A. S., Sadoff, J. C., Iglewski, B. H., Sokol, P. A. Evidence for the role of toxin A in the pathogenesis of infection withPseudomonas aeruginosa in humans. J. Inf. Dis. 142 (1984) 538–546.
Pollack, M. Antibody-mediated immunity in Pseudomonas disease and its clinical application. Infect. Immun. 15 (1977) 776–780.
Young, L. S.: Gram-negative septicemia: Antibody deficiency and specific protection. Bayer Symposium VIII. The pathogenesis of bacterial infection: 1985, 138–145.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Class, I., Junginger, W. & Klöss, T. Einsatz von Pseudomonas-Immunglobulin bei beatmeten Patienten einer interdisziplinären chirurgischen Intensivstation. Infection 15 (Suppl 2), S67–S70 (1987). https://doi.org/10.1007/BF01644196
Issue Date:
DOI: https://doi.org/10.1007/BF01644196